July was a month about ownership. Not compliance, not litigation skill – ownership. Google’s edge sits on TPU technology that competitors must come back and license. Sanofi lost the mRNA product...
What happens when intellectual property built into your products turns out to belong to someone else? This week supplied three expensive answers. Each involved one of the world’s most powerful companies...
Over the past two decades, US firm value flipped from mostly tangible to over 90% intangible — and the rulebook for defending those intangibles quietly rewrote itself underneath everyone. A recent...
The most valuable intellectual property in your business is often not the product your customers see — it’s the platform underneath it: the data it learned from, the delivery technology it...
What actually decides an IP dispute — the strength of your rights, or the machinery around them? This past week delivered three very different answers to that question, and each one...
Intellectual property rarely fails loudly. It fails in the gap between filing and follow-through — the priority date no one re-checked, the order no one renewed, the AI agent no one...
The most valuable lesson in intellectual property this week wasn’t a single ruling — it was a pattern. Across a landmark licensing deal, a patent that collapsed over one character, and...
A former engineer leaves, starts a company, and files a patent. Months later the original employer discovers the application describes technology that looks remarkably like a project the engineer worked on...
IP Organiser’s recently compiled record of every pharmaceutical patent term extension granted in Australia maps roughly 1,600 extended patents across 850 products, and the patterns are worth reading closely. Activity is...
Amending the basis of your validity challenge in patent litigation is never just a procedural move — it is a strategic play with real commercial consequences. What stands out in AstraZeneca...
You must be logged in to post a comment.